REFERENCES
- Briseid K, Hoem NO, Johannesen S, Vangen AM, Westgaard T. Significance of IgG for the activity of factor XII measured in human plasma. Scand J Clin Lab Invest 1996; 56: 725–34.
- Briseid K, Hoem NO, Johannesen S. Part of prekallikrein removed from human plasma together with IgG-immunoblot experiments and functional tests. Scand J Clin Lab Invest 1999; 59: 55–64.
- De La Cadena RA, Wachtfogel YT, Colman RW. Contact activation pathway: inflammation and coagulation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and throm-bosis, 3rd ed. Philadelphia: Lippincott; 1994. p. 219–40.
- Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819–43.
- Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50–68.
- Aberg H, Nilsson IM. Recurrent thrombosis in a young woman with a circulating anticoagulant directed against factors XI and XII. Acta Med Scand 1972; 192: 419–24.
- Stern DM, Nossel HL, Owen J. Acquired anti-body to FXI in a patient with congenital factor XI deficiency. J Clin Invest 1982; 69: 1270–6.
- De La Cadena RA, Baglia FA, Johnson CA, et al. Naturally occurring antibodies against two distinct functional domains in the heavy chain of FXI/ FXIa. Blood 1988; 72: 1748–54.
- Page JD, De La Cadena RA, Humphries JE, Colman RW. An autoantibody to human plasma prekallikrein blocks activation of the contact system. Br J Haematol 1994; 87: 81–6.
- Mary JY, Modigliani R. Development and validation of a Crohn's disease endoscopic index. Gut 1989; 30: 983–9.
- Fossum S, Hoem NO, Gjonnxss H, Briseid K. Contact activation factors in plasma from women on estrogen replacement therapy after ovario-hysterectomy. Thromb Res 1999; 93: 161–70.
- Brandtzaeg P, Haraldsen G, Rugtveit J. Immuno-pathology of human inflammatory bowel disease. Springer Semin Immunopathol 1997; 18: 555–89.
- Philipsen EK, Bondesen S, Andersen J, Larsen S. Serum immunoglobulin G subclasses in patients with ulcerative colitits and Crohn's disease of different disease activities. Scand J Gastroenterol 1995; 30: 50–3.
- Kjeldsen J, Schaffalitzky de Muckadell OB. Assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastro-enterol 1993; 28: 1–9.
- Tans G, Janssen-Claessen T, Rosing J, Griffin JH. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kalli-krein and factor XIa. Eur J Biochem 1987; 164: 637 —42.
- Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 1980; 20: 149–62.
- Chong GL, Reeck GR. Interaction of trypsin, 13-factor XIIa, and plasma kallikrein with a trypsin inhibitor isolated from barley seeds: a comparison with the corn inhibitor of activated Hageman factor. Thromb Res 1987; 48: 211–21.
- Briseid K, Hoem NO, Johannesen S, Haug K. Amidolytic assay of factor XI in human plasma—significance of kallikrein for the activity measured. Thromb Res 1995; 78: 239–50.
- Ito R, Statland BE. Centrifugal analysis for plasma kallikrein activity, with use of the chromo-genic substrate S-2302. Clin Chem 1981; 27: 586–93.
- Retzios AD, Rosenfeld R, Schiffman S. Enzymes of the contact phase of blood coagulation: kinetics with various chromogenic substrates and a two-substrate assay for the joint estimation of plasma prekallikrein and factor XI. J Lab Clin Med 1988; 112: 560–66.
- Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, Briseid K. Contact factors in plasma from women on oral contra-ception—significance of factor XI for the meas-ured activity of factor XII. Thromb Res 1994; 74: 477— 85.